Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $4,937 | $5,001 | $5,029 | $4,835 |
| - Cash | $2,176 | $2,001 | $1,689 | $2,243 |
| + Debt | $2,370 | $2,849 | $2,978 | $3,200 |
| Enterprise Value | $5,131 | $5,849 | $6,318 | $5,792 |
| Revenue | $1,423 | $1,394 | $1,212 | $1,232 |
| % Growth | 2.1% | 15.1% | -1.6% | – |
| Gross Profit | $497 | $381 | $405 | $363 |
| % Margin | 34.9% | 27.3% | 33.4% | 29.5% |
| EBITDA | $323 | $201 | -$130 | $181 |
| % Margin | 22.7% | 14.4% | -10.8% | 14.7% |
| Net Income | $265 | $157 | -$133 | $116 |
| % Margin | 18.6% | 11.2% | -11% | 9.5% |
| EPS Diluted | 0.18 | 0.11 | -0.091 | 0.079 |
| % Growth | 63.6% | 221% | -214.5% | – |
| Operating Cash Flow | $505 | $544 | $0 | $0 |
| Capital Expenditures | -$40 | -$41 | -$62 | -$53 |
| Free Cash Flow | $465 | $503 | $339 | $444 |